Tool
APOB Calculator
Estimate Apolipoprotein B from a standard lipid panel using the Sniderman regression. Direct apoB immunoassay is the gold standard — this is an estimate when you don't have one.
Your lipid panel
All values from a standard fasting or non-fasting panel.
Estimated APOB
Sniderman regression
— mg/dL
Primary estimate.
non-HDL / 1.4 (sanity check)
— mg/dL
Rough heuristic; underestimates at high TG.
Interpretation
Enter your values to see an estimate.
Target: <60 aggressive · <80 standard
If your APOB is above target
Top-ranked interventions on the APOB tier list. Tier reflects evidence, cost, access, and effect — all things considered.
- S High-Intensity Statin
Anchor intervention. Multiple RCT generations across primary + secondary prevention. Rosuvastatin slightly edges atorvastatin on apoB head-to-head.
- A Ezetimibe
Add-on to statin drops APOB another 10–15% and cuts MACE 6.4% in IMPROVE-IT. Modest effect, but the first non-statin LDL drug with hard-outcome proof.
- A Bempedoic Acid
For statin-intolerant patients, drops APOB 9–13% and cuts MACE 13% in CLEAR Outcomes. One landmark trial keeps it at evidence B until replicated; watch uric acid.
Disclaimer. Educational content. Not medical advice. Discuss results with a clinician before changing treatment.
Method. Primary estimate uses the Sniderman regression apoB ≈ −33.12 + 0.675 × non-HDL-C + 11.95 × ln(TG) (mg/dL). Known error inflates above TG ~400 mg/dL — a direct apoB immunoassay is recommended in that range and is the gold standard at any TG.